Daktarės jehnen neurologijos klinika, MB - financials and debts

Company age: 3 y. 11 mo.

Update

Daktarės jehnen neurologijos klinika - Company finances

EUR
2022
From: 2022-10-24
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 0 1,490 12,780 15,100
Profit before tax -778 -12,002 -12,346 -190
Net profit -778 -12,002 -12,346 -190
Equity -778 -13,492 -25,061 -23,913
Liabilities 778 13,492 25,978 24,978
Non-current assets 0 0 0 0
Current assets 0 0 917 1,065
Total assets 0 0 917 1,065
Taxes paid
STI taxes - 127 - -
Financial indicators
Revenue change y/y - - +757.7% +18.2%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. - - -1346.3% -17.8%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. - - - -
Profit margin Net profit margin. Shows the overall profitability of the company. - -805.5% -96.6% -1.3%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. - -805.5% -96.6% -1.3%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - - - -
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - - - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Daktarės jehnen neurologijos klinika - Social security debts

The company had no debts to Sodra

Daktarės jehnen neurologijos klinika - VMI tax arrears

The company had no tax arrears (debts) to the State Tax Inspectorate

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Daktares jehnen neurologijos klinika, MB (code 306165175) is a Small partnership operating in medical specialists activities. In 2025, the company generated revenue of €15.1K, up 18.1% year on year and far above the €1.5K reported in 2023. The top line has therefore expanded strongly over the latest three years, although profitability remains limited. Net loss narrowed to €190 in 2025 from €12.3K in 2024 and €12.0K in 2023, bringing the profit margin close to break-even at -1.3% in the latest year. The balance sheet remains small: total assets were €1.1K in 2025, compared with €917 in 2024, while liabilities stood at €25.0K and equity remained negative at €23.9K. This means the company continues to operate with a stretched capital structure and negative net assets. Reported return and leverage ratios are affected by the negative equity base and the very small asset position, so they should be interpreted cautiously. Overall, 2025 shows a clear improvement in operating performance, but the company still has to rebuild equity to strengthen its financial position.